Clinical implication of autoantibodies in patients with systemic rheumatic diseases

References

• Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv. Immunol.33, 167–240 (1982).
   PubMed Web of Science ®Google Scholar
• Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol.44, 93–151 (1989).
   PubMed Web of Science ®Google Scholar
• Reeves WH, Narain S, Satoh M. Autoantibodies in systemic lupus erythematosus. In: Arthritis and Allied Conditions. A Textbook of Rheumatology. Koopman WJ, Moreland LW (Eds). Lippincott Williams and Wilkins, PA, USA 1497–1521 (2005).
   Google Scholar
• Reeves WH, Satoh M, Richards HB. Origins of antinuclear antibodies. In: Systemic Lupus Erythematosus. Lahita RG (Ed.) Academic Press, CA, USA 401–431 (2004).
   Google Scholar
• Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.25(11), 1271–1277 (1982).
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.40(9), 1725 (1997).
   PubMed Web of Science ®Google Scholar
• Reeves WH, Satoh M, Lyons R, Nichols C, Narain S. Detection of autoantibodies against proteins and ribonucleoproteins by double immunodiffusion, immunoprecipitation, and western blotting. In: Manual of Molecular and Clinical Laboratory Immunology (7th Edition). Rose NR, Hamilton RG, Detrick B, Reeves WH (Eds). American Society of Microbiology Press, DC, USA 1007–1018 (2006).
   Google Scholar
• Sharp GC, Irvin WS, May CM et al. Association of autoantibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic diseases. N. Engl. J. Med.295(21), 1149–1154 (1976).
   PubMed Web of Science ®Google Scholar
• Fritzler MJ, Fritzler ML. The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. Curr. Med. Chem.13(21), 2503–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Balboni I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, Utz PJ. Multiplexed protein array platforms for analysis of autoimmune diseases. Annu. Rev. Immunol.24, 391–418 (2006).
   PubMed Web of Science ®Google Scholar
• Chan EKL. Autoantibodies and the cloning and characterization of cellular constituents. In: Autoantibodies and Autoimmunity: Molecular Mechanisms in Health and Disease. Pollard KM (Ed.) Wiley-VCH Verlag GmbH&Co.KGaA, Weinheim 419–446 (2006).
   Google Scholar
• Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin. Liver Dis.25(3), 298–310 (2005).
   PubMed Web of Science ®Google Scholar
• Hsieh MY, Dai CY, Lee LP et al. The antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in chronic hepatitis C patients. J. Clin. Pathol. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Tan EM, Feltkamp TE, Smolen JS et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum.40(9), 1601–1611 (1997).
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Kanestrom A, Madland TM, Thomassen E, Haga HJ, Vollset SE. Evaluation of diagnostic tests for antinuclear antibodies in rheumatological practice. Scand. J. Immunol.52(3), 309–315 (2000).
   PubMed Web of Science ®Google Scholar
• Bonilla E, Francis L, Allam F et al. Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin. Immunol.124(1), 18–21 (2007).
   PubMed Web of Science ®Google Scholar
• Kidd K, Cusi K, Mueller R, Goodner M, Boyes B, Hoy E. Detection and identification of significant ANAs in previously determined ANA negative samples. Clin. Lab.51(9–10), 517–521 (2005).
   PubMed Web of Science ®Google Scholar
• Fujinaga H, Takuchi K, Kaneda K, Takasaki Y, Hashimoto H. Analysis of autoantibodies to cell cycle-associated antigens. Mod. Rheumatol.11(3), 222–229 (2001).
   PubMedGoogle Scholar
• Yamasaki Y, Honkanen-Scott M, Hernandez L et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum.54(9), 3051–3056 (2006).
   PubMedGoogle Scholar
• Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am.28(4), 859–890 (2002).
   PubMed Web of Science ®Google Scholar
• Jakymiw A, Lian S, Eystathioy T et al. Disruption of GW bodies impairs mammalian RNA interference. Nat. Cell Biol.7(12), 1267–1274 (2005).
   PubMed Web of Science ®Google Scholar
• Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol. Biol. Cell13(4), 1338–1351 (2002).
   PubMed Web of Science ®Google Scholar
• Jakymiw A, Pauley KM, Li S et al. The role of GW/P-bodies in RNA processing and silencing. J. Cell Sci.120(Pt 8), 1317–1323 (2007).
   PubMed Web of Science ®Google Scholar
• Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK. Autoimmune targeting of key components of RNA interference. Arthritis Res. Ther.8(4), R87 (2006).
   Web of Science ®Google Scholar
• Yu JH, Yang WH, Gulick T, Bloch KD, Bloch DB. Ge-1 is a central component of the mammalian cytoplasmic mRNA processing body. RNA11(12), 1795–1802 (2005).
   PubMed Web of Science ®Google Scholar
• Satoh M, Langdon JJ, Chou CH et al. Characterization of the Su antigen, a macromolecular complex of 100/102 and 200 kDa proteins recognized by autoantibodies in systemic rheumatic diseases. Clin. Immunol. Immunopathol.73(1), 132–141 (1994).
   PubMedGoogle Scholar
• Nozawa K, Fritzler MJ, Chan EK. Unique and shared features of Golgi complex autoantigens. Autoimmun. Rev.4(1), 35–41 (2005).
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin P, Qiu S et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int. J. Oncol.30(5), 1137–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Gentric A, Blaschek MA, Le Noach JF et al. Serological arguments for classifying Raynaud’s phenomenon as idiopathic. J. Rheumatol.17(9), 1177–1181 (1990).
   PubMedGoogle Scholar
• Nakabayashi T, Kumagai T, Yamauchi K et al. Evaluation of the automatic fluorescent image analyzer, Image Titer, for quantitative analysis of antinuclear antibodies. Am. J. Clin. Pathol.115(3), 424–429 (2001).
   PubMedGoogle Scholar
• Mosca M, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases in 2004. Clin. Exp. Rheumatol.22(3 Suppl. 33), S14–S18 (2004).
   PubMed Web of Science ®Google Scholar
• Bodolay E, Csiki Z, Szekanecz Z et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin. Exp. Rheumatol.21(3), 313–320 (2003).
   PubMed Web of Science ®Google Scholar
• De Angelis R, Cerioni A, Del Medico P, Blasetti P. Raynaud’s phenomenon in undifferentiated connective tissue disease (UCTD). Clin. Rheumatol.24(2), 145–151 (2005).
   PubMedGoogle Scholar
• Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am. J. Med.52(2), 148–159 (1972).
   PubMed Web of Science ®Google Scholar
• Sharp GC. MCTD: a concept which stood the test of time. Lupus11(6), 333–339 (2002).
   PubMedGoogle Scholar
• Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum.42(5), 899–909 (1999).
   PubMed Web of Science ®Google Scholar
• Buchanan RR, Riglar AG. The titre of anti-centromere antibodies: its relationship to Raynaud’s phenomenon and vascular occlusion. Br. J. Rheumatol.28(3), 221–226 (1989).
   PubMedGoogle Scholar
• Zhao Z, Weinstein E, Tuzova M et al. Cross-reactivity of human lupus anti-DNA antibodies with α-actinin and nephritogenic potential. Arthritis Rheum.52(2), 522–530 (2005).
   PubMedGoogle Scholar
• Kowal C, Degiorgio LA, Lee JY et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl Acad. Sci. USA103(52), 19854–19859 (2006).
   PubMed Web of Science ®Google Scholar
• Lee LA. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun. Rev.4(4), 207–213 (2005).
   PubMed Web of Science ®Google Scholar
• Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum. Dis. Clin. North Am.33(2), 267–285 (2007).
   PubMed Web of Science ®Google Scholar
• Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med. Sci. Monit.10(11), CR615–CR621 (2004).
   PubMedGoogle Scholar
• Nadashkevich O, Davis P, Fritzler MJ. Revising the classification criteria for systemic sclerosis. Arthritis Rheum.55(6), 992–993 (2006).
   PubMedGoogle Scholar
• Tanimoto K, Nakano K, Kano S et al. Classification criteria for polymyositis and dermatomyositis. J. Rheumatol.22(4), 668–674 (1995).
   PubMed Web of Science ®Google Scholar
• Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol.9(6), 527–535 (1997).
   PubMedGoogle Scholar
• Dorph C, Lundberg IE. Idiopathic inflammatory myopathies – myositis. Best Pract. Res. Clin. Rheumatol.16(5), 817–832 (2002).
   PubMedGoogle Scholar
• Akizuki M. [Symposium on immunology in internal medicine. 1. Autoantibodies and diseases.] J. Jap. Soc. Int. Med.77(10), 1494–1497 (1988).
   PubMedGoogle Scholar
• Yamasaki Y, Narain S, Yoshida H et al. Autoantibodies to RNA helicase A: a new serological marker of early lupus. Arthritis Rheum.56(2), 596–604 (2007).
   PubMedGoogle Scholar
• Katsumi S, Kobayashi N, Yamamoto Y, Miyagawa S, Shirai T. Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody. Br. J. Dermatol.142(5), 1030–1033 (2000).
   PubMedGoogle Scholar
• Sato S, Hirakata M, Kuwana M et al. Autoantibodies to a 140-kD polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum.52(5), 1571–1576 (2005).
   PubMed Web of Science ®Google Scholar
• Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum.54(11), 3682–3689 (2006).
   PubMed Web of Science ®Google Scholar
• Kaji K, Fujimoto M, Hasegawa M et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxf.)46(1), 25–28 (2007).
   PubMed Web of Science ®Google Scholar
• Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann. Rheum. Dis. DOI: 10.1136/ard.2006.068502 (2007) (Epub ahead of print).
   Google Scholar
• Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann. Rheum. Dis.61(6), 554–558 (2002).
   PubMed Web of Science ®Google Scholar
• Franceschini F, Cavazzana I, Generali D et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J. Rheumatol.29(7), 1393–1397 (2002).
   PubMed Web of Science ®Google Scholar
• Mimori T. Clinical significance of anti-Ku autoantibodies – a serologic marker of overlap syndrome? Intern. Med.41(12), 1096–1098 (2002).
   PubMed Web of Science ®Google Scholar
• Hirakata M. Humoral aspects of polymyositis/dermatomyositis. Mod. Rheumatol.10(4), 199–206 (2000).
   PubMedGoogle Scholar
• Yamasaki Y, Yamada H, Nozaki T et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum.54(6), 2004–2009 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin. Arthritis Rheum.26, 459–467 (1996).
   PubMed Web of Science ®Google Scholar
• Hirakata M, Suwa A, Takada T et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum.56(4), 1295–1303 (2007).
   PubMed Web of Science ®Google Scholar
• Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum.48(8), 2285–2293 (2003).
   PubMed Web of Science ®Google Scholar
• O’Hanlon TP, Rider LG, Mamyrova G et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum.54(11), 3670–3681 (2006).
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun. Rev.4(5), 253–263 (2005).
   PubMed Web of Science ®Google Scholar
• Kallenberg CG, Stegeman CA, Bootsma H, Bijl M, Limburg PC. Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful? Lupus15(7), 397–402 (2006).
   PubMedGoogle Scholar
• Riboldi P, Gerosa M, Moroni G et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity38(1), 39–45 (2005).
   PubMed Web of Science ®Google Scholar
• Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J. Rheumatol.33(9), 1785–1788 (2006).
   PubMed Web of Science ®Google Scholar
• Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum.55(6), 900–904 (2006).
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Dieker JW, McGrath FD et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann. Rheum. Dis.66(5), 693–696 (2007).
   PubMed Web of Science ®Google Scholar
• Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus13(5), 290–297 (2004).
   PubMed Web of Science ®Google Scholar
• Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum. Dis. Clin. North Am.22(4), 709–735 (1996).
   PubMed Web of Science ®Google Scholar
• Medsger TAJ. Systemic sclerosis (scleroderma): clinical aspects. In: Arthritis and Allied Conditions. A Textbook of Rheumatology. Koopman WJ (Ed.) Lippincott Williams & Wilkins, PA, USA 1590–1624 (2001).
   Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum.35(1), 35–42 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J. Rheumatol.34(1), 104–109 (2007).
   PubMed Web of Science ®Google Scholar
• Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum.48(1), 203–209 (2003).
   PubMed Web of Science ®Google Scholar
• Dick T, Mierau R, Bartz-Bazzanella P et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann. Rheum. Dis.61(2), 121–127 (2002).
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann. Rheum. Dis.61(9), 842–846 (2002).
   PubMedGoogle Scholar
• Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum.50(1), 209–215 (2004).
   PubMed Web of Science ®Google Scholar
• Elkon KB, Bonfa E, Llovet R, Eisenberg RA. Association between anti-Sm and anti-ribosomal P protein autoantibodies in human systemic lupus erythematosus and MRL/lpr mice. J. Immunol.143(5), 1549–1554 (1989).
   PubMed Web of Science ®Google Scholar
• Kameda H, Kuwana M, Hama N, Kaburaki J, Homma M. Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases. J. Rheumatol.24(2), 400–403 (1997).
   PubMedGoogle Scholar
• Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med.349(16), 1526–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J. Rheumatol.29(11), 2345–2349 (2002).
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand. J. Immunol.54(1–2), 211–219 (2001).
   PubMed Web of Science ®Google Scholar
• Tan EM, Smolen JS, McDougal JS et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum.42(3), 455–464 (1999).
   PubMed Web of Science ®Google Scholar
• Dahle C, Skogh T, Aberg AK, Jalal A, Olcen P. Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J. Autoimmun.22(3), 241–248 (2004).
   PubMed Web of Science ®Google Scholar
• Miyachi K, Tan EM. Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases. Arthritis Rheum.22(1), 87–93 (1979).
   PubMedGoogle Scholar
• Elkon K, Skelly S, Parnassa A et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA83(19), 7419–7423 (1986).
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Caponi L, Franceschini F et al. Diagnostic tests for antiribosomal P protein antibodies: a comparative evaluation of immunoblotting and ELISA assays. J. Autoimmun.19(1–2), 71–77 (2002).
   PubMedGoogle Scholar
• Lin JL, Dubljevic V, Fritzler MJ, Toh BH. Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus. Clin. Exp. Immunol.141(1), 155–164 (2005).
   PubMedGoogle Scholar
• Karassa FB, Afeltra A, Ambrozic A et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum.54(1), 312–324 (2006).
   PubMed Web of Science ®Google Scholar
• Gussin HA, Ignat GP, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum.44(2), 376–383 (2001).
   PubMedGoogle Scholar
• Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A. Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin. Rheumatol.25(4), 542–543 (2006).
   PubMedGoogle Scholar
• Hirakata M, Suwa A, Nagai S et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J. Immunol.162(4), 2315–2320 (1999).
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet362(9388), 971–982 (2003).
   PubMed Web of Science ®Google Scholar
• Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA et al. Anti-Th/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J. Rheumatol.33(8), 1600–1605 (2006).
   PubMedGoogle Scholar
• Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest130(4), 976–981 (2006).
   PubMedGoogle Scholar
• Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J. Rheumatol.32(8), 1488–1494 (2005).
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Narain S, Hernandez L et al. Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Res. Ther.8(4), R111–R120 (2006).
   PubMed Web of Science ®Google Scholar
• Tomkiel JE, Alansari H, Tang N et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin. Cancer Res.8(3), 752–758 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang JY, Wang X, Peng XX, Chan EK. Autoantibody responses in Chinese hepatocellular carcinoma. J. Clin. Immunol.22(2), 98–105 (2002).
   PubMedGoogle Scholar
• Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Gejyo F. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J. Rheumatol.27(6), 1403–1407 (2000).
   PubMed Web of Science ®Google Scholar
• Respaldiza N, Wichmann I, Ocana C et al. Anti-centromere antibodies in patients with systemic lupus erythematosus. Scand. J. Rheumatol.35(4), 290–294 (2006).
   PubMed Web of Science ®Google Scholar
• Gelber AC, Pillemer SR, Baum BJ et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann. Rheum. Dis.65(8), 1028–1032 (2006).
   PubMed Web of Science ®Google Scholar
• Avouac J, Sordet C, Depinay C et al. Systemic sclerosis-associated Sjogren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum.54(7), 2243–2249 (2006).
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Tonutti E, Villalta D et al. Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study. The Italian Society of Laboratory Medicine Study Group on the Diagnosis of Autoimmune diseases. Clin. Chem.46(10), 1681–1685 (2000).
   PubMedGoogle Scholar
• Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum.52(8), 2425–2432 (2005).
   PubMed Web of Science ®Google Scholar
• van der Linden MW, Westendorp RG, Zidane M, Meheus L, Huizinga TW. Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens. J. Rheumatol.28(2), 284–287 (2001).
   PubMedGoogle Scholar
• Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum.52(4), 1138–1147 (2005).
   PubMed Web of Science ®Google Scholar
• Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren’s syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin. Immunol. Immunopathol.36(1), 120–128 (1985).
   PubMedGoogle Scholar
• Yamagata H, Akizuki M, Tojo T, Homma M. Anti-Ro/SSA and -La/SSB antibodies in patients with connective tissue diseases. Scand. J. Rheumatol.61, 98–101 (1986).
   Google Scholar
• Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EK. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J. Hepatol.46(1), 107–114 (2007).
   PubMed Web of Science ®Google Scholar
• Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and malignancies. Am. J. Pathol.140(4), 859–870 (1992).
   PubMed Web of Science ®Google Scholar
• Watanabe A, Kodera M, Sugiura K et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum.50(3), 892–900 (2004).
   PubMed Web of Science ®Google Scholar
• Wu T, Tanguay RM. Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe? Cell Stress Chaperones11(1), 1–12 (2006).
   PubMedGoogle Scholar
• Reeves WH, Satoh M, Wang J, Chou CH, Ajmani AK. Autoantibodies to DNA, DNA-binding proteins, and histones. Rheum. Dis. Clin. North Am.20(1), 1–28 (1994).
   PubMedGoogle Scholar
• James JA, Mamula MJ, Harley JB. Sequential autoantigenic determinants of the small nuclear ribonucleoprotein Sm D shared by human lupus autoantibodies and MRL lpr/lpr antibodies. Clin. Exp. Immunol.98(3), 419–426 (1994).
   PubMedGoogle Scholar
• Harley JB, James JA. Autoepitopes in lupus. J. Lab. Clin. Med.126(6), 509–516 (1995).
   PubMedGoogle Scholar
• Satoh M, Ajmani AK, Ogasawara T et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J. Clin. Invest.94(5), 1981–1989 (1994).
   PubMedGoogle Scholar
• Satoh M, Akaogi J, Kuroda Y et al. Autoantibodies that stabilize U1snRNPs are a significant component of human autoantibodies to snRNPs and delay proteolysis of the Sm antigens. J. Rheumatol.31, 2382–2389 (2004).
   PubMedGoogle Scholar
• Fritzler MJ. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus15(7), 422–427 (2006).
   PubMed Web of Science ®Google Scholar
• Zhuang H, Narain S, Sobel E et al. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin. Immunol.117(3), 238–250 (2005).
   PubMed Web of Science ®Google Scholar
• Mahler M, Fritzler MJ, Bluthner M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res. Ther.7(1), R19–R29 (2005).
   PubMed Web of Science ®Google Scholar